Pfenex Inc (PFNX)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Pfenex Inc (PFNX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014086
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:50
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Pfenex Inc (Pfenex) is a biologics company that develops biosimilar therapeutics. The company’s lead product candidate includes, PF582, a biosimilar candidate which is used for the treatment of retinal diseases. It also develops PF530, a biosimilar candidate for the treatment of multiple sclerosis; PF708, a peptide product candidate to treat high-risk fracture patients; and others. Pfenex’s preclinical products under development include PF529, a biosimilar candidate to neulasta; PF688, a biosimilar candidate to cimzia, PF444, PF690; and others. The company produces biosimilar product with protein production platform and bioanalytic approach. It partners with the US government for developing vaccines for anthrax and malaria. Pfenex is headquartered in San Diego, California, the US.

Pfenex Inc (PFNX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Pfenex Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Pfenex Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Pfenex Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Pfenex Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Pfenex Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Pfenex Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Pfenex Enters into Research Agreement with Path Vaccine Solutions 11
Pfenex Forms Joint Venture With Agila Biotech 12
Pfenex Enters Into Co-Development Agreement With DNA2.0 13
Pfenex Enters Into Co-Development Agreement With ProZyme 14
Pfenex Enters Into Collaboration With MedImmune 15
Pfenex Enters Into Collaboration With Boehringer Ingelheim 16
Licensing Agreements 17
Jazz Pharma Enters into Licensing Agreement with Pfenex 17
Nemucore Medical Enters into Licensing Agreement with Pfenex 19
Equity Offering 20
Pfenex Raises USD40.4 Million in Public Offering of Shares 20
Pfenex Raises USD50 Million in IPO 22
Pfenex Inc – Key Competitors 23
Pfenex Inc – Key Employees 24
Pfenex Inc – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
Nov 09, 2017: Pfenex Reports Third Quarter 2017 Results, Interim PK data from PF708 Study, Completion of Process Development Milestone on Jazz Program and Provides Business Update 26
Aug 09, 2017: Pfenex Reports Second Quarter 2017 Results and Provides Business Update 28
May 08, 2017: Pfenex Reports First Quarter 2017 Results and Provides Business Update 30
Mar 15, 2017: Pfenex Reports Fourth Quarter and Full Year 2016 Results and Provides Business Update 32
Nov 09, 2016: Pfenex Reports Third Quarter 2016 Results and Provides Business Update 34
Aug 08, 2016: Pfenex Reports Second Quarter 2016 Results and Provides Business Update 36
May 09, 2016: Pfenex Reports First Quarter 2016 Results and Provides Business Update 38
Mar 10, 2016: Pfenex Reports Fourth Quarter and Full Year 2015 Results and Provides Business Update 40
Corporate Communications 42
Sep 07, 2017: Pfenex Announces Management Changes 42
Aug 03, 2017: Pfenex Names Eef Schimmelpennink Chief Executive Officer 43
Apr 03, 2017: Sigurdur (Siggi) Olafsson And Jason Grenfell-Gardner Nominated To Serve On Board Of Directors 44
Mar 31, 2017: William R. Rohn Announces Plans To Retire As Chairman And Board Member 45
Jan 24, 2017: Pfenex Announces Leadership Transition 46
Product News 47
08/08/2016: Pfenex to Regain Full Rights to PF582 and Announces Phase 1/2 Results 47
Clinical Trials 48
Aug 08, 2016: Pfenex Announces Positive Anthrax Vaccine Study Results 48
May 09, 2016: Pfenex Reports Positive Top-Line Bioequivalence Data for PF708 49
Appendix 50
Methodology 50
About GlobalData 50
Contact Us 50
Disclaimer 50

List of Tables
Pfenex Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Pfenex Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Pfenex Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Pfenex Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Pfenex Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Pfenex Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Pfenex Enters into Research Agreement with Path Vaccine Solutions 11
Pfenex Forms Joint Venture With Agila Biotech 12
Pfenex Enters Into Co-Development Agreement With DNA2.0 13
Pfenex Enters Into Co-Development Agreement With ProZyme 14
Pfenex Enters Into Collaboration With MedImmune 15
Pfenex Enters Into Collaboration With Boehringer Ingelheim 16
Jazz Pharma Enters into Licensing Agreement with Pfenex 17
Nemucore Medical Enters into Licensing Agreement with Pfenex 19
Pfenex Raises USD40.4 Million in Public Offering of Shares 20
Pfenex Raises USD50 Million in IPO 22
Pfenex Inc, Key Competitors 23
Pfenex Inc, Key Employees 24
Pfenex Inc, Subsidiaries 25

★海外企業調査レポート[Pfenex Inc (PFNX)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Medusa Mining Ltd:企業の戦略・SWOT・財務分析
    Medusa Mining Ltd - Strategy, SWOT and Corporate Finance Report Summary Medusa Mining Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Osaka Gas Co Ltd (9532):企業の財務・戦略的SWOT分析
    Osaka Gas Co Ltd (9532) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • BPCE SA:企業のM&A・事業提携・投資動向
    BPCE SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's BPCE SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital ra …
  • Cadila Pharmaceuticals Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Cadila Pharmaceuticals Ltd (Cadila Pharmaceuticals) is a pharmaceutical company that develops, manufactures and distributes pharmaceutical products. The company's products include active pharmaceutical ingredients (API) and pharmaceutical formulations. Its business includes contract research …
  • The Centre of Excellence for Prevention of Organ Failure:医療機器:M&Aディール及び事業提携情報
    Summary The Centre of Excellence for Prevention of Organ Failure (PROOF Centre) is a healthcare center that provides blood-based biomarker tests. The center conducts biomarker programs to develop simple blood tests for transplant patients and patients with chronic organ disease and biomarkers in tra …
  • RigNet Inc (RNET):石油・ガス:M&Aディール及び事業提携情報
    Summary RigNet Inc (RigNet) is a technology company that provides applications, customized communication services and cyber security solutions. Its managed services include remote communications and technology services for onshore and offshore drilling rigs, support vessels, production facilities, a …
  • Park Group plc:企業の戦略・SWOT・財務情報
    Park Group plc - Strategy, SWOT and Corporate Finance Report Summary Park Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Faisal Islamic Bank of Egypt (SAE):企業の戦略的SWOT分析
    Faisal Islamic Bank of Egypt (SAE) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Archroma Management GmbH:企業の戦略的SWOT分析
    Archroma Management GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Carmat SAS (ALCAR):企業の財務・戦略的SWOT分析
    Summary Carmat SAS (Carmat) is a medical equipment company that provides artificial organs. The company provides development of innovative artificial organs, artificial heart and other vital organs, among others. Carmat artificial heart products consist of an implantable heart. The company offers co …
  • Pangaea Biotech SL:企業の製品パイプライン分析2018
    Summary Pangaea Biotech SL (Pangaea) is a provider of molecular diagnostics and research and development services for cancer treatment. The company discovers and develops gene signatures and prognostic markers. Its services include molecular diagnosis, in vitro drug testing, clinical trials, biomark …
  • Dome Investments Public Company Limited:企業の戦略・SWOT・財務情報
    Dome Investments Public Company Limited - Strategy, SWOT and Corporate Finance Report Summary Dome Investments Public Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Natural Beauty Bio-Technology Ltd.:戦略・SWOT・企業財務分析
    Natural Beauty Bio-Technology Ltd. - Strategy, SWOT and Corporate Finance Report Summary Natural Beauty Bio-Technology Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Confo Therapeutics:製薬・医療:M&Aディール及び事業提携情報
    Summary Confo Therapeutics is a drug discovery company that conducts research and development of g protein coupled receptors targeted therapeutics. The company offers CONFO body technology. Its technology uses confobody stabilized functional conformations of g protein coupled receptors. Confo Therap …
  • Kier Group Plc (KIE):企業の財務・戦略的SWOT分析
    Kier Group Plc (KIE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • QGEP Participacoes SA (QGEP3):企業の財務・戦略的SWOT分析
    Summary QGEP Participacoes SA (QGEP), a subsidiary of Queiroz Galvao Group, is an oil and gas company that explores, develops and produces oil and gas properties. The company's exploration properties include Santos Basin, Espirito Santo Basin, Camamu-Almada Basin, Sergipe-Alagoas Basin, Pernambuco-P …
  • Theradex Systems Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Theradex Systems Inc (Theradex) is a research organization that provides clinical trials monitoring services. The organization develops medical devices, pharmaceutical compounds and diagnostic tests in the areas of oncology and life-threatening diseases. It provides services such as clinical …
  • Nanion Technologies GmbH:医療機器:M&Aディール及び事業提携情報
    Summary Nanion Technologies GmbH (Nanion) is a biotechnology company that develops new innovations in the field of ion channel research and screening. The company offers products such as port-a-patch, patchliner, syncropatch 96, syncropatch 384pe, npc-chips, vesicle prep pro, ordering information, s …
  • Steelcase Inc.:企業の戦略・SWOT・財務分析
    Steelcase Inc. - Strategy, SWOT and Corporate Finance Report Summary Steelcase Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Sompo Holdings, Inc. (8630):企業の財務・戦略的SWOT分析
    Sompo Holdings, Inc. (8630) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆